# Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)

> **NCT03617263** · PHASE2 · TERMINATED · sponsor: **Zydus Therapeutics Inc.** · enrollment: 60 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease in Women With PCOS

## Interventions

- **DRUG:** Saroglitazar Magnesium 4 mg Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03617263
- **Lead sponsor:** Zydus Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-12
- **Primary completion:** 2024-10-28
- **Final completion:** 2024-10-28
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03617263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03617263, "Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03617263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*